Guardant Health (NASDAQ:GH) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

Guardant Health (NASDAQ:GH) had its target price lifted by stock analysts at The Goldman Sachs Group from $36.00 to $49.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. The Goldman Sachs Group’s price target would suggest a potential upside of 2.30% from the stock’s current price.

A number of other research firms have also recently commented on GH. Sanford C. Bernstein reduced their price target on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. Guggenheim restated a “buy” rating on shares of Guardant Health in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. upped their target price on shares of Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Leerink Partners cut their target price on Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Finally, Barclays started coverage on shares of Guardant Health in a report on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 target price for the company. Sixteen research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $42.63.

Guardant Health Stock Up 2.0 %

Shares of GH stock traded up $0.92 during trading hours on Tuesday, hitting $47.90. 218,529 shares of the company’s stock traded hands, compared to its average volume of 2,513,354. Guardant Health has a 12 month low of $15.81 and a 12 month high of $49.86. The stock has a market cap of $5.92 billion, a PE ratio of -11.27 and a beta of 1.28. The stock’s 50 day simple moving average is $35.62 and its 200 day simple moving average is $29.68.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The company had revenue of $191.48 million during the quarter, compared to analyst estimates of $170.49 million. During the same period in the prior year, the firm earned ($0.73) earnings per share. Guardant Health’s revenue was up 33.9% compared to the same quarter last year. As a group, equities research analysts expect that Guardant Health will post -3.44 EPS for the current fiscal year.

Insider Activity

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the business’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the sale, the director now directly owns 2,676 shares of the company’s stock, valued at $93,660. The trade was a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Meghan V. Joyce sold 2,896 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total value of $86,590.40. Following the transaction, the director now owns 7,648 shares in the company, valued at approximately $228,675.20. The trade was a 27.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,548 shares of company stock worth $179,782. 5.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Guardant Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Guardant Health by 19.4% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company’s stock valued at $44,732,000 after purchasing an additional 238,037 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Guardant Health by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,198 shares of the company’s stock worth $800,000 after purchasing an additional 2,537 shares in the last quarter. R Squared Ltd bought a new stake in shares of Guardant Health in the 4th quarter worth $26,000. KBC Group NV raised its holdings in shares of Guardant Health by 63.6% during the fourth quarter. KBC Group NV now owns 5,658 shares of the company’s stock valued at $173,000 after purchasing an additional 2,200 shares during the last quarter. Finally, Wealthcare Advisory Partners LLC purchased a new stake in Guardant Health during the 4th quarter valued at $252,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.